{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:24:11Z","timestamp":1791300251296,"version":"4.1.0"},"reference-count":51,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>In the past decade, several studies have reported that patients with chronic myeloproliferative neoplasms (MPNs) have an increased risk of second solid cancer or lymphoid hematological cancer. In this qualitative review study, we present results from studies that report on these cancer risks in comparison to cancer incidences in the general population or a control group. Our literature search identified 12 such studies published in the period 2009\u20132018 including analysis of more than 65,000 patients. The results showed that risk of solid cancer is 1.5- to 3.0-fold elevated and the risk of lymphoid hematological cancer is 2.5- to 3.5-fold elevated in patients with MPNs compared to the general population. These elevated risks apply to all MPN subtypes. For solid cancers, particularly risks of skin cancer, lung cancer, thyroid cancer, and kidney cancer are elevated. The largest difference in cancer risk between patients with MPN and the general population is seen in patients below 80 years. Cancer prognosis is negatively affected due to cardiovascular events, thrombosis, and infections by a concurrent MPN diagnosis mainly among patients with localized cancer. Our review emphasizes that clinicians caring for patients with MPNs should be aware of the very well-documented increased risk of second non-myeloid cancers.<\/jats:p>","DOI":"10.3390\/cancers12103061","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T20:50:07Z","timestamp":1603227007000},"page":"3061","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Risks of Solid and Lymphoid Malignancies in Patients with Myeloproliferative Neoplasms: Clinical Implications"],"prefix":"10.3390","volume":"12","author":[{"given":"Mette","family":"Brabrand","sequence":"first","affiliation":[{"name":"Department of Haematology, Odense University Hospital, 5000 Odense, Denmark"},{"name":"Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, 5000 Odense, Denmark"},{"name":"Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Frederiksen","sequence":"additional","affiliation":[{"name":"Department of Haematology, Odense University Hospital, 5000 Odense, Denmark"},{"name":"Department of Clinical Epidemiology, Aarhus University Hospital, 8200 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"key":"ref_1","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., Arber, D.A., Hasserjian, R.P., and Le Beau, M.M. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Agency for Research on Cancer (IARC)."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/cncr.21297","article-title":"Leukemic transformation of polycythemia vera: A single center study of 23 patients","volume":"104","author":"Passamonti","year":"2005","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and Personalized Prognosis in Myeloproliferative Neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/CLEP.S162688","article-title":"Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: A nationwide population-based survey in Denmark","volume":"11","author":"Brochmann","year":"2019","journal-title":"Clin. Epidemiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: A population-based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2147\/CLEP.S216787","article-title":"Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms - Impact Of Comorbidity","volume":"11","author":"Frederiksen","year":"2019","journal-title":"Clin. Epidemiol."},{"key":"ref_9","first-page":"1197","article-title":"A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database","volume":"57","author":"Brunner","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: A Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","article-title":"Second malignancies in patients with myeloproliferative neoplasms: A population-based cohort study of 9379 patients","volume":"32","author":"Landtblom","year":"2018","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/ejh.12410","article-title":"Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis","volume":"94","author":"Pettersson","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S2352-3026(18)30108-X","article-title":"Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: A nationwide, observational follow up study in Sweden","volume":"5","author":"Chattopadhyay","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","article-title":"Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy","volume":"304","author":"Berk","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: Long-term follow-up of a randomized clinical trial","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/10428199609074368","article-title":"Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: A prospective analysis of 682 cases. The \u201cFrench Cooperative Group for the Study of Polycythaemias\u201d","volume":"22","author":"Najean","year":"1996","journal-title":"Leuk. Lymphoma"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3324\/haematol.2010.033191","article-title":"The JAK2 V617F somatic mutation, mortality and cancer risk in the general population","volume":"96","author":"Nielsen","year":"2011","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2009-07-235119","article-title":"Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"115","author":"Thoennissen","year":"2010","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study","volume":"33","author":"Barbui","year":"2019","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1179\/102453308X316022","article-title":"Second malignancies in essential thrombocythemia (ET): A retrospective analysis of 331 patients with long-term follow-up from a single institution","volume":"13","author":"Radaelli","year":"2008","journal-title":"Hematology"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Fallah, M., Kharazmi, E., Sundquist, J., and Hemminki, K. (2011). Higher risk of primary cancers after polycythaemia vera and vice versa. Br. J. Haematol.","DOI":"10.1111\/j.1365-2141.2010.08538.x"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10428194.2015.1071492","article-title":"Risk of second primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study","volume":"57","author":"Khanal","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3324\/haematol.2010.033779","article-title":"Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: A study of 1915 patients","volume":"96","author":"Rumi","year":"2011","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood-2011-12-401455","article-title":"Risk of second cancers in chronic myeloproliferative neoplasms","volume":"119","author":"Susini","year":"2012","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1055-9965.EPI-09-0353","article-title":"Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"18","author":"Vannucchi","year":"2009","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(15)00092-7","article-title":"Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: A population-based cohort study","volume":"2","author":"Frederiksen","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.5306\/wjco.v7.i4.324","article-title":"Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia","volume":"7","author":"Shrestha","year":"2016","journal-title":"World J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3109\/10428194.2015.1041392","article-title":"Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera\u2014Single center experience","volume":"57","author":"Masarova","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","article-title":"Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study","volume":"33","author":"Hultcrantz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V89.7.2319","article-title":"Treatment of polycythemia vera: Use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group","volume":"89","author":"Najean","year":"1997","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ferrari, A., Carobbio, A., Masciulli, A., Ghirardi, A., Finazzi, G., De Stefano, V., Vannucchi, A.M., and Barbui, T. (2019). Clinical outcomes under hydroxyurea treatment in polycythemia vera: A systematic review and meta-analysis. Haematologica.","DOI":"10.3324\/haematol.2019.221234"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/ejh.12787","article-title":"Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms","volume":"98","author":"Hansen","year":"2017","journal-title":"Eur J Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/cam4.1081","article-title":"Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia","volume":"6","author":"Santoro","year":"2017","journal-title":"Cancer Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","article-title":"Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy","volume":"132","author":"Porpaczy","year":"2018","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: Is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Hasselbalch, H.C., and Bjorn, M.E. (2015). MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. Mediat. Inflamm., 2015.","DOI":"10.1155\/2015\/102476"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1182\/blood-2011-03-340992","article-title":"Increase in circulating CD4(+)CD25(+)Foxp3(+) T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-alpha","volume":"118","author":"Riley","year":"2011","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjh.16321","article-title":"Smoking, blood cells and myeloproliferative neoplasms: Meta-analysis and Mendelian randomization of 2.3 million people","volume":"189","author":"Jayasuriya","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Pedersen, K.M., Colak, Y., Hasselbalch, H.C., Ellervik, C., Nordestgaard, B.G., and Bojesen, S.E. (2020). Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study. EClinicalMedicine, 21.","DOI":"10.1016\/j.eclinm.2020.100295"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Troelsen, F.S., Farkas, D.K., Ording, A.G., Erichsen, R., Jick, S., and Sorensen, H.T. (2019). Prevalence of Colorectal Neoplasms and Mortality in New Users of Low-Dose Aspirin With Lower Gastrointestinal Bleeding. Am. J. Ther.","DOI":"10.1016\/S0016-5085(19)38041-2"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1016\/S0016-5085(19)38042-4","article-title":"Chemoprevention of colorectal cancer in the general population: An umbrella metaanalysis","volume":"156","author":"Bardou","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41375-019-0616-4","article-title":"Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin","volume":"34","author":"Barbui","year":"2019","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ajh.25700","article-title":"Second cancers in MPN: Survival analysis from an international study","volume":"95","author":"Marchetti","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1158\/1055-9965.EPI-06-0416","article-title":"Identifying and screening patients at risk of second cancers","volume":"15","author":"Vogel","year":"2006","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_50","unstructured":"Rothman, K.J., Greenland, S., and Lash, T.L. (2008). Modern Epidemiology, Lippincott Williams & Wilkins. [3rd ed.]."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The hazards of hazard ratios","volume":"21","author":"Hernan","year":"2010","journal-title":"Epidemiology"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/10\/3061\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:24:48Z","timestamp":1760178288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/10\/3061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["cancers12103061"],"URL":"https:\/\/doi.org\/10.3390\/cancers12103061","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]}}}